AssetMark Inc
KNSA icon

AssetMark Inc’s Kiniksa Pharmaceuticals KNSA Stock Holding History

AssetMark Inc’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.21K Buy
43
+38
+760% +$2.8K ﹤0.01% 2903
2026
Q2 		$320 Hold
5
– – ﹤0.01% 3365
2026
Q1 		$241 Hold
5
– – ﹤0.01% 3302
2025
Q4 		$206 Hold
5
– – ﹤0.01% 3250
2025
Q3 		$194 Buy
+5
New +$162 ﹤0.01% 3068

Other funds holding KNSA

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Lisanti Capital Growth
Lisanti Capital Growth New York $373M AUM 178.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

AssetMark Inc's KNSA Position: Q3 2026 in Review

AssetMark Inc increased its Kiniksa Pharmaceuticals (KNSA) stake by 760% in Q3 2026, buying an estimated $2.8K and bringing the position to 43 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

AssetMark Inc first reported a position in KNSA in Q3 2025 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • AssetMark Inc held 43 shares of Kiniksa Pharmaceuticals worth $3.21K as of Q3 2026.
  • AssetMark Inc bought 38 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $2.8K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #2903 holding.
  • AssetMark Inc first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.